Pfizer vaccine booster highly effective in late-stage trial

A booster of Pfizer-BioNTech’s COVID-19 vaccine has proved highly effective in warding off disease from the dominant delta strain of the coronavirus, according to preliminary results of a late-stage trial. 

The booster dose was 95.6% at preventing disease, compared to those who didn’t receive an extra shot in …

For the full story: Read More

Leave a Reply

Your email address will not be published. Required fields are marked *